Descrizione

The global cancer vaccines market is set to grow by US$ 3 miliardi durante 2021-2027, crescendo ad un tasso di crescita annuale composto (CAGR) Di 8.2% durante il periodo di previsione, secondo la società di dati e analisi StrategyHelix. Increase in prevalence of cancer worldwide, rising investments and government funding in the development of cancer vaccines, rise in development of new cancer vaccines, launch and approval of new cancer vaccines in the market are expected to boost the market growth in the coming years.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2017-2020 e previsione a 2027 covering key market aspects like sales value for cancer vaccines. The global cancer vaccines market is segmented on the basis of product, applicazione, tecnologia, e regione. Per prodotto, it is categorized into preventative vaccines, and therapeutic vaccines. The preventative vaccines segment held the largest market share in 2020. Per applicazione, the cancer vaccines market is divided into cervical cancer, liver cancer, prostate cancer, e altri. The cervical cancer segment accounted for the largest market share in 2020. Based on technology, the cancer vaccines market is divided into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.

The report has profiled some of the key players of the market such as Amgen Inc., Anixa Biosciences Inc. (ANIX), Dendreon Corporation, Dendreon Pharmaceuticals LLC, eTheRNA immunotherapies NV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Immunicum AB, Inovio Pharmaceuticals Inc., Merck KGaA, Moderna Inc., OSE Immunotherapeutics SA, Providence Therapeutics Holdings Inc., Sanofi SA, UbiVac Inc., Vaccinogen Inc..

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the cancer vaccines market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Prodotto: preventative vaccines, and therapeutic vaccines
Applicazione: cervical cancer, liver cancer, prostate cancer, e altri
Tecnologia: dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines
Regione: Nord America, Asia Pacifico, Europa, and Rest of the World (RIGA)
Anni considerati: la presente relazione copre il periodo 2017 A 2027

Principali vantaggi per gli stakeholder

Get a comprehensive picture of the global cancer vaccines market
Identificare le strategie regionali e le priorità strategiche sulla base di dati e analisi locali
Individuare i settori in crescita e le tendenze per gli investimenti
Understand what the future of the global cancer vaccines market looks like
Identificare il panorama competitivo e la finestra di opportunità

Sommario

1. Definizione del mercato
2. Metodologia di ricerca
3. Dati di mercato & Veduta
3.1 Valore di mercato
3.2 Previsione del valore di mercato
4. Cancer Vaccines Market by Product
4.1 Preventative Vaccines
4.2 Therapeutic Vaccines
5. Cancer Vaccines Market by Application
5.1 Cervical Cancer
5.2 Liver Cancer
5.3 Prostate Cancer
5.4 Altri
6. Cancer Vaccines Market by Technology
6.1 Dendritic Cells (Dc) Cancer Vaccines
6.2 Recombinant Cancer Vaccines
6.3 Antigen/Adjuvant Cancer Vaccines
6.4 Viral Vector & Dna Cancer Vaccines
7. Cancer Vaccines Market by Region
7.1 Nord America
7.2 Asia Pacifico
7.3 Europa
7.4 Rest Of The World (Row)
8. Profili aziendali
8.1 Amgen Inc.
8.2 Anixa Biosciences, Inc. (ANIX)
8.3 Dendreon Corporation
8.4 Dendreon Pharmaceuticals LLC
8.5 eTheRNA immunotherapies NV
8.6 F. Hoffmann-La Roche Ltd.
8.7 GlaxoSmithKline plc
8.8 Immunicum AB
8.9 Inovio Pharmaceuticals, Inc.
8.10 Merck KGaA
8.11 Moderna, Inc.
8.12 OSE Immunotherapeutics SA
8.13 Providence Therapeutics Holdings Inc.
8.14 Sanofi SA
8.15 UbiVac, Inc.
8.16 Vaccinogen Inc.
9. Appendice
9.1 Informazioni su StrategyHelix
9.2 Disclaimer